EDAP Earnings

EDAP reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 16.01M against an estimate of 15.05M, resulting in a 6.41% surprise. The EPS was -0.15, surpassing the expected -0.26 by 42.31%. The stock experienced a -4.33% price change on the earnings day and a -2.88% change over the next five days, reflecting market reactions to the results.

Following EDAP's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -4.33% on the day of the release. Over the subsequent five days, it saw a -2.88% change. Historically, EDAP's stock price tends to shift by an average of 10.62% in the 10 days leading up to earnings and -1.19% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate EDAP's annual revenue to reach 20.50M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EDAP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EDAP's stock price typically moves by 10.62% in the 10 days before its earnings and -1.19% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.14 and revenue of 20.50M.

The earnings call reflects strong growth in the core HIFU business, with record revenue and significant increases in HIFU revenue and placements. The strategic financing with EIB and the new CPT code for BPH treatment are positive developments. Although there are concerns about the declining noncore business and operating losses, the optimistic guidance and strategic investments in HIFU suggest a positive outlook. The Q&A session confirmed positive trends in U.S. procedures and payer coverage. Overall, these factors indicate a likely positive stock price movement.